Follow us:

Microsoft Pri0

Welcome to Microsoft Pri0: That's Microspeak for top priority, and that's the news and observations you'll find here from Seattle Times technology reporter Matt Day.

October 30, 2007 at 5:24 PM

Nastech slips on Wall Street

Nastech Pharmaceuticals had a rough time in the market Tuesday in the wake of its most recent quarterly earnings report.

Shares fell 13.27 percent to $12.88 as the Bothell firm – which specializes in delivering therapies through its proprietary nasal spray technology – saw its quarterly loss more than double to $16.4 million.

Profits are not as meaningful in early-stage biomedical companies such as Nastech, which derive most of their income from research partnerships and investors, as they are in other, commercial-stage companies. But the sudden drop in the company’s numbers seems to have spooked some shareholders.

The loss, the company said in an earnings statement Monday, came as lower revenue coincided with higher research expenditures and an expanded payroll.

Comments | More in Biotechnology

COMMENTS

No personal attacks or insults, no hate speech, no profanity. Please keep the conversation civil and help us moderate this thread by reporting any abuse. See our Commenting FAQ.



The opinions expressed in reader comments are those of the author only, and do not reflect the opinions of The Seattle Times.


The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►
The Seattle Times

To keep reading, you need a subscription upgrade.

We hope you have enjoyed your complimentary access. For unlimited seattletimes.com access, please upgrade your digital subscription.

Call customer service at 1.800.542.0820 for assistance with your upgrade or questions about your subscriber status.

The Seattle Times

To keep reading, you need a subscription.

We hope you have enjoyed your complimentary access. Subscribe now for unlimited access!

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Activate Subscriber Account ►